Sponsor Pipeline

Kelly Fitzgerald, MD Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
1
Active Trials
1
Recruiting
1
Disease Areas
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-28 NCT07043608
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases		 Recruitment opened
2026-07-28 NCT07043608
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases		 date change Primary completion pushed: 2029-02-28 -> 2029-04-30
2026-07-28 NCT07043608
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases		 date change Completion pushed: 2030-02-28 -> 2030-04-30
Active Trials by Phase
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07043608 Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Clear Cell Renal Cell Cancer (ccRCC) Recruiting
Disease Areas
Kidney Cancer (1)
Get alerts when Kelly Fitzgerald, MD's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free